Effects of angiotensin II on insulin receptor binding and mRNA levels in normal and diabetic rats

• Published in: Diabetologia Vol. 40; no. 7; pp. 770 - 777
• Main Authors: SECHI, L. A, GRIFFIN, C. A, ZINGARO, L, VALENTIN, J.-P, BARTOLI, E, SCHAMBELAN, M
• Format: Journal Article
• Language: English
• Published: Berlin Springer 01.07.1997
• Subjects: Angiotensin II - pharmacology; Animals; Biological and medical sciences; Blood Glucose - metabolism; Blood Pressure - drug effects; Body Weight - drug effects; Captopril - pharmacology; Diabetes Mellitus, Experimental - blood; Diabetes Mellitus, Experimental - physiopathology; Diabetes. Impaired glucose tolerance; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Insulin - blood; Kidney - drug effects; Kidney - metabolism; Liver - drug effects; Liver - metabolism; Male; Medical sciences; Organ Size - drug effects; Rats; Rats, Sprague-Dawley; Receptor, Insulin - biosynthesis; Receptor, Insulin - metabolism; Reference Values; Renin - blood; RNA, Messenger - metabolism; RNA, Ribosomal, 28S - metabolism; Transcription, Genetic - drug effects; Endocrinopathy; Ligand binding; Pancreatic hormone; Rat; Digestive system; Liver; Rodentia; Experimental study; Gene expression; Non insulin dependent diabetes; Insulin; Kidney; Renin angiotensin system; Vertebrata; Mammalia; Urinary system; Animal; Angiotensin II; Hormonal receptor
• ISSN: 0012-186X; 1432-0428
• DOI: 10.1007/s001250050748

Both the density and level of mRNA encoding insulin receptors in the kidney are inversely related to the dietary sodium content, suggesting a feedback mechanism that limits the insulin-induced sodium retention when extracellular fluid volume is expanded. Because angiotensin II affects tissue sensitivity to insulin in humans, we investigated whether angiotensin II affects insulin receptor binding and mRNA levels in the kidney, liver, and renal arteries of normal rats and rats with streptozotocin-induced diabetes mellitus. Non-diabetic and diabetic rats were infused for 7 days with either vehicle or angiotensin II at a rate of 200 ng. kg-1. min-1. In a separate experiment, normal rats were treated with an angiotensin converting enzyme inhibitor (captopril, 100 mg/dl in the drinking water) or vehicle for 7 days. Regional analysis of insulin receptor binding in the kidney and renal arteries was performed by an in situ technique using computerized microdensitometry and emulsion autoradiography. Insulin receptor mRNA levels were determined in renal and hepatic tissue by Northern blot hybridization and normalized with 28S rRNA. No differences in blood pressure were observed among diabetic and non-diabetic rats infused with either vehicle or angiotensin II, whereas captopril-treated rats had significantly lower blood pressure levels than their respective controls. Angiotensin II significantly decreased plasma renin concentration in both non-diabetic and diabetic rats. Insulin receptor number was significantly greater in the renal cortex of diabetic rats than in non-diabetics, whereas no significant differences were found in the outer medulla, inner medulla, or renal arteries. Angiotensin II infusion did not affect either the number or affinity of insulin receptors in any of the renal regions studied. Insulin receptor mRNA levels were significantly greater in the kidney and liver of diabetic rats than in non-diabetics and were not affected by angiotensin II infusion. Similar to angiotensin II infusion, captopril treatment did not affect either renal insulin receptor binding or mRNA levels. Thus, diabetic rats have increased insulin receptor binding and mRNA levels in comparison to non-diabetic rats. Angiotensin II infusion and captopril treatment do not affect insulin receptor binding and mRNA levels in the kidney, arguing against a role for this peptide in the modulation of renal sensitivity to insulin.